Table 1.
Clinicopathologic characteristics in LIHC cohort according to PARD3 expression.
| Characteristics | level | Low expression of PARD3 | High expression of PARD3 | p-value |
|---|---|---|---|---|
| n | 186 | 185 | ||
| Gender (%) | Female | 56 (30.1%) | 65 (35.1%) | 0.356 |
| Male | 130 (69.9%) | 120 (64.9%) | ||
| Race (%) | Asian | 78 (44.3%) | 80 (43.7%) | 0.983 |
| Black or African | 8 (4.5%) | 9 (4.9%) | ||
| White | 90 (51.1%) | 94 (51.4%) | ||
| T stage (%) | T1 | 105 (57.4%) | 76 (41.1%) | 0.006† |
| T2 | 43 (23.5%) | 51 (27.6%) | ||
| T3 | 32 (17.5%) | 48 (25.9%) | ||
| T4 | 3 (1.6%) | 10 (5.4%) | ||
| N stage (%) | N0 | 125 (99.2%) | 127 (97.7%) | 0.622‡ |
| N1 | 1 (0.8%) | 3 (2.3%) | ||
| M stage (%) | M0 | 132 (99.2%) | 134 (97.8%) | 0.622‡ |
| M1 | 1 (0.8%) | 3 (2.2%) | ||
| Pathologic stage (%) | Stage I | 100 (57.5%) | 71 (41.0%) | 0.006†,‡ |
| Stage II | 41 (23.6%) | 45 (26.0%) | ||
| Stage III | 31 (17.8%) | 54 (31.2%) | ||
| Stage IV | 2 (1.1%) | 3 (1.7%) | ||
| Tumor status (%) | Tumor free | 108 (61.4%) | 93 (52.8%) | 0.132 |
| With tumor | 68 (38.6%) | 83 (47.2%) | ||
| Residual tumor (%) | R0 | 172 (97.2%) | 152 (92.1%) | 0.023†,‡ |
| R1 | 4 (2.3%) | 13 (7.9%) | ||
| R2 | 1 (0.6%) | 0 (0.0%) | ||
| Histologic grade (%) | G1 | 36 (19.6%) | 19 (10.4%) | 0.023† |
| G2 | 92 (50.0%) | 85 (46.7%) | ||
| G3 | 52 (28.3%) | 70 (38.5%) | ||
| G4 | 4 (2.2%) | 8 (4.4%) | ||
| Adjacent hepatic tissue inflammation (%) | Mild | 46 (37.4%) | 53 (47.7%) | 0.144 |
| None | 69 (56.1%) | 48 (43.2%) | ||
| Severe | 8 (6.5%) | 10 (9.0%) | ||
| Child–Pugh grade (%) | A | 118 (91.5%) | 99 (90.0%) | 0.810‡ |
| B | 10 (7.8%) | 11 (10.0%) | ||
| C | 1 (0.8%) | 0 (0.0%) | ||
| Fibrosis Ishak score (%) | 0 | 47 (39.8%) | 27 (28.7%) | 0.405 |
| 1–2 | 16 (13.6%) | 15 (16.0%) | ||
| 3–4 | 15 (12.7%) | 13 (13.8%) | ||
| 5–6 | 40 (33.9%) | 39 (41.5%) | ||
| Vascular invasion (%) | No | 116 (72.0%) | 90 (58.4%) | 0.016† |
| Yes | 45 (28.0%) | 64 (41.6%) | ||
| TP53 status (%) | Mut | 40 (22.2%) | 62 (34.8%) | 0.012† |
| WT | 140 (77.8%) | 116 (65.2%) | ||
| Age (median [IQR]) | 61.50 [53.00, 69.00] | 60.50 [51.00, 69.00] | 0.329 | |
| Height (median [IQR]) | 168.00 [161.50, 174.00] | 168.00 [161.00, 173.00] | 0.590 | |
| Weight (median [IQR]) | 72.00 [60.00, 84.00] | 68.00 [59.00, 81.00] | 0.210 | |
| BMI (median [IQR]) | 24.84 [22.14, 28.88] | 24.19 [21.24, 28.43] | 0.256 | |
| AFP (ng/ml) (median [IQR]) | 10.00 [3.00, 52.00] | 28.00 [5.00, 1456.00] | 0.001† | |
| Alb (g/dl) (median [IQR]) | 4.00 [3.42, 4.40] | 4.00 [3.55, 4.30] | 0.520 | |
| PT (s) (median [IQR]) | 1.10 [1.00, 8.93] | 1.10 [1.00, 9.57] | 0.538 |
Mut mutant, WT wild type, BMI body mass index, AFP alpha fetoprotein, Alp albumin, TB total bilirubin, PT prothrombin time.
†Statistically significant.
‡Fisher exact test.